Physician profile
Matthew Mischel
NPI 1013996172
$2,029.61
in general payments reported to CMS, 2019-2025
23 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $112 · 2021: $48.44 · 2022: $108 · 2023: $512 · 2024: $129 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734 · Education: $51.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.05 |
| Education | $51.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $357.61 | 2019-2025 | Evenity |
| Outset Medical INC | $261.05 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $217.49 | 2019 | |
| Philips North America LLC | $195.68 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $145.20 | 2019-2024 | Rexulti |
| Abbott Laboratories | $140.45 | 2023 | Proclaim |
| Glaxosmithkline, LLC. | $131.44 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $90.54 | 2021-2025 | |
| Novo Nordisk INC | $72.37 | 2019-2024 | Ozempic |
| Amarin Pharma, INC. | $64.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.21 | 2022 | |
| Opko Pharmaceuticals, LLC | $53.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $30.98 | 2023 | |
| Pfizer INC. | $25.50 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $22.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.60 | 2019 | |
| Lilly USA, LLC | $20.84 | 2023 | Mounjaro |
| Akebia Therapeutics INC | $20.32 | 2019 | |
| Eisai INC. | $18.89 | 2019 | |
| Vertiflex, INC. | $18.27 | 2019 | |
| Exact Sciences Corporation | $17.16 | 2025 | Cologuard Collection Kit |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mischel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.